Yuji Shibata

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

30h-index2.8kcitations177works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(61), Cancer Genomics and Diagnostics(29), Lung Cancer Research Studies(16), Cancer Immunotherapy and Biomarkers(12), Lung Cancer Diagnosis and Treatment(10)

Publications176 total

Supplementary Tables S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025Open Access
Supplementary Figures S1-S4 from A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non–Small Cell Lung Cancer (LC-SCRUM-Liquid)
2025Open Access
Clinical concordance of Pan Lung Cancer PCR Panel covering 167 actionable variants across 11 genes and other validated assays in the LC-SCRUM-Asia registry
JTO Clinical and Research Reports·2025Open Access
Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations
Cancer Research·2025· 1 cited
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
Lung Cancer·2025
Fabrication of a polycarbonate/polypropylene fiber mix air filter using a melt-blowing apparatus with different nozzle diameters
Journal of Textile Engineering·2025· 1 citedOpen Access
Efficacy and safety of upfront radiotherapy with immune checkpoint inhibitors for brain metastasis in non-small cell lung cancer
Cancer Treatment and Research Communications·2025Open Access
A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score)
Future Oncology·2024· 2 citedOpen Access
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
Lung Cancer·2024· 6 cited
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib
Journal of Thoracic Oncology·2024· 6 cited
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).
Journal of Clinical Oncology·2024· 2 cited
Clinical-genomic characteristics in patients with EGFR-mutated non-small cell lung cancer harboring MET copy number gains after progression on EGFR-TKI: A report from LC-SCRUM-TRY.
Journal of Clinical Oncology·2024
OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer.
Journal of Clinical Oncology·2024· 8 cited
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
Lung Cancer·2024· 10 cited
LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion
Communications Biology·2024· 3 citedOpen Access
Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance
Cancer Research·2024
Prognostic value of predominant subtype in pathological stage II–III lung adenocarcinoma with epidermal growth factor receptor mutation
Lung Cancer·2023· 4 cited
P2.13-06 A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer
Journal of Thoracic Oncology·2023Open Access
LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
Annals of Oncology·2023· 13 citedOpen Access
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
Journal of Thoracic Oncology·2023· 16 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Nobuyuki Horita(11), Takeshi Kaneko(11), Kentaro Nakashima(10), Hiroki Watanabe(9), Kiyotaka Yoh(9), Kenjiro Nagai(8), Takashi Sato(8), Kōichi Goto(8), Terufumi Kato(8), Tetsuro Kawaguchi(7), Masaki Yamamoto(7), Hideyuki Nagakura(7), Ken Tashiro(7), Ryota Ushio(7), Hibiki Udagawa(7), Hiroki Izumi(7), Kohkichi Hosoda(6), Toshinori Tsukahara(6), Shingo Matsumoto(6), Naoki Furuya(6)